Pure Bioscience (PURE) President reports insider stock and option positions

Rhea-AI Filing Summary

Pure Bioscience, Inc.11/17/2025. He directly holds 12,998 shares of Pure Bioscience common stock. In addition, he holds several stock option awards giving him the right to buy common shares at exercise prices ranging from $0.07 to $0.79 per share, with expiration dates extending through 2034. Earlier option grants from 2020 through 2024 are already fully vested, while an option granted on September 23, 2025 for 300,000 shares is scheduled to vest in four equal installments on December 23, 2025, March 23, 2026, June 23, 2026, and September 23, 2026.

11/28/2025 - 06:25 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kitchell Jeffrey Scott

(Last) (First) (Middle)

771 JAMACHA RD., #512

(Street)

EL CAJON CA 92019

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/17/2025

3. Issuer Name and Ticker or Trading Symbol
PURE BIOSCIENCE, INC. [ PURE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Corporate Secretary

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	12,998	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	(1)	01/29/2030	Common Stock	45,000	$0.33	D
Stock Options (Right to Buy)	(2)	05/15/2030	Common Stock	45,000	$0.79	D
Stock Options (Right to Buy)	(3)	06/18/2031	Common Stock	70,000	$0.45	D
Stock Options (Right to Buy)	(4)	09/30/2032	Common Stock	90,000	$0.2	D
Stock Options (Right to Buy)	(5)	08/01/2033	Common Stock	150,000	$0.12	D
Stock Options (Right to Buy)	(6)	08/20/2034	Common Stock	155,000	$0.07	D
Stock Options (Right to Buy)	(7)	09/23/2025	Common Stock	300,000	$0.074	D

Explanation of Responses:

1. The option was granted on January 29, 2020 and became fully vested on January 29, 2021.

2. The option was granted on May 15, 2020 and became fully vested on May 15, 2021.

3. The option was granted on June 18, 2021 and became fully vested on June 18, 2022.

4. The option was granted on September 30, 2022 and became fully vested on September 30, 2023.

5. The option was granted on August 1, 2023 and became fully vested on August 1, 2024.

6. The option was granted on August 20, 2024 and became fully vested on August 20, 2025.

7. The option was granted on September 23, 2025. The option shares shall vest and become exercisable in four equal installments on December 23, 2025, March 23, 2026, June 23, 2026, and September 23, 2026.

	/s/ Jeffrey Scott Kitchell	11/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.